Pubblicazioni

Autori:

Caminati, Marco; Maule, Matteo; Benoni, Roberto; Micheletto, Claudio; Tecchio, Cristina; Vaia, Rachele; DE FRANCESCHI, Lucia; Guarnieri, Gabriella; Vianello, Andrea; Senna, Gianenrico

Titolo:

Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance

Anno:

2023

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

ORPHANET JOURNAL OF RARE DISEASES

ISSN Rivista:

1750-1172

Intervallo pagine:

302-307

Parole chiave:

IL5, idiopathic hyperosinophilic syndrome,

Breve descrizione dei contenuti:

Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosinophilic syndrome (HES) without any identifiable non-hematologic secondary cause. According to the available real-life evidence mepolizumab 300 mg and 100 mg, licensed for severe eosinophilic asthma, are comparable in terms of drug efficacy. However, the clinical rationale for selecting one dose or the other has not been explored. We investigated the efficacy and safety of mepolizumab 100 mg in idiopathic HES (I-HES) patients as a steroid sparing strategy for disease remission maintenance by assessing clinical conditions, blood eosinophil count (BEC) and adverse events at baseline and at 3–6–12 months follow-up. Overall, 11 patients were enrolled (females 4–36%) with a median age of 62 years (IQR 55.0–72.0). At 3-month visit both prednisone daily dose and BEC significantly decreased from baseline, whilst a substantial improvement of Brief fatigue inventory score (BFI) was not recorded before the 6 months assessment. More than 70% of patients completely stopped prednisone at 12-months follow-up, without any flare in terms of BEC and BFI. No adverse event was registered. Although larger studies are needed, our report firstly describes that in a well-defined population, diagnosed with I-HES and in disease remission, low dose mepolizumab is a safe and effective steroid-sparing option for remission maintenance. It suggests that a personalized treatment dose might be explored according to the disease classification and activity at the time of biologic treatment start.

Id prodotto:

139918

Handle IRIS:

11562/1127427

ultima modifica:

30 ottobre 2024

Citazione bibliografica:

Caminati, Marco; Maule, Matteo; Benoni, Roberto; Micheletto, Claudio; Tecchio, Cristina; Vaia, Rachele; DE FRANCESCHI, Lucia; Guarnieri, Gabriella; Vianello, Andrea; Senna, Gianenrico, Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance «ORPHANET JOURNAL OF RARE DISEASES» , 2023 , pp. 302-307

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo